Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751141 | 0.87 | CA1 (0.49) | CA1CA2CA9ATMCYP2C19 | |
| SCHEMBL28741529 | 0.87 | EPAS1 (0.41) | CA1CA2CA9CYP2C19ALDH1A1 | |
| SCHEMBL29365046 | 0.85 | CA1 (0.50) | CA1CA2CA9ATMCYP2C19 | |
| SCHEMBL1772862 | 0.85 | CA1 (0.50) | CA1CA2CA9ATMCYP2C19 | |
| SCHEMBL19179633 | 0.85 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL3952428 | 0.84 | KIF11 (0.37) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL2454881 | 0.84 | CA1 (0.49) | CA1CA2CA9ATMCYP2C19 | |
| SCHEMBL29909456 | 0.83 | CYP2C19 (0.52) | CA1CA2CA9ATMCYP2C19 | |
| SCHEMBL4066885 | 0.83 | CYP2C19 (0.52) | CA1CA2CA9ATMCYP2C19 | |
| SCHEMBL4517030 | 0.81 | CA1 (0.49) | CA1CA2CA9ATMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | CA1 4376/4885CA2 2610/4885CA9 2741/4885 |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | CA1 2067/4885CA2 267/4885CA9 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.